1. Yang, J. W. et al. Recent advances of animal model of focal segmental glomerulosclerosis. Clin. Exp. Nephrol. 22, 752–763 (2018).
2. Pereira Wde, F. et al. Te experimental model of nephrotic syndrome induced by Doxorubicin in rodents: An update. Infamm. Res. 64, 287–301 (2015).
3. Wang, Y., Wang, Y. P., Tay, Y. C. & Harris, D. C. Progressive adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events. Kidney Int. 58, 1797–1804 (2000).
4. Nikolic-Paterson, D. J., Lan, H. Y., Hill, P. A. & Atkins, R. C. Macrophages in renal injury. Kidney Int. Suppl. 45, S79–S82 (1994).
5. Ni, Y. et al. Plectin protects podocytes from adriamycin-induced apoptosis and F-actin cytoskeletal disruption through the integrin alpha6beta4/FAK/p38 MAPK pathway. J. Cell. Mol. Med. 22, 5450–5467 (2018).
6. Potter, L. R., Abbey-Hosch, S. & Dickey, D. M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 27, 47–72 (2006).
7. Goetze, J. P. et al. Cardiac natriuretic peptides. Nat. Rev. Cardiol. 17, 698–717 (2020).
8. Fuller, F. et al. Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J. Biol. Chem. 263, 9395–9401 (1988).
9. Suga, S. et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 130, 229–239 (1992).
10. Bennett, B. D. et al. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J. Biol. Chem. 266, 23060–23067 (1991).
11. Matsukawa, N. et al. Te natriuretic peptide clearance receptor locally modulates the physiological efects of the natriuretic peptide system. Proc. Natl. Acad. Sci. U.S.A. 96, 7403–7408 (1999).
12. Nagase, M., Katafuchi, T., Hirose, S. & Fujita, T. Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats. J. Hypertens. 15, 1235–1243 (1997).
13. Ogawa, Y. et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J. Am. Soc. Nephrol. 23, 1198–1209 (2012).
14. Kato, Y. et al. Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition. Sci. Rep. 7, 46624. https://doi.org/10.1038/srep46624 (2017).
15. Wilcox, J. N., Augustine, A., Goeddel, D. V. & Lowe, D. G. Diferential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol. Cell. Biol. 11, 3454–3462 (1991).
16. Tomas, G. et al. Osteocrin, a novel bone-specifc secreted protein that modulates the osteoblast phenotype. J. Biol. Chem. 278, 50563–50571 (2003).
17. Nishizawa, H. et al. Musclin, a novel skeletal muscle-derived secretory factor. J. Biol. Chem. 279, 19391–19395 (2004).
18. Mofatt, P. et al. Osteocrin is a specifc ligand of the natriuretic Peptide clearance receptor that modulates bone growth. J. Biol. Chem. 282, 36454–36462 (2007).
19. Chiba, A. et al. Osteocrin, a peptide secreted from the heart and other tissues, contributes to cranial osteogenesis and chondrogenesis in zebrafsh. Development 144, 334–344 (2017).
20. Miyazaki, T. et al. A new secretory peptide of natriuretic peptide family, osteocrin, suppresses the progression of congestive heart failure afer myocardial infarction. Circ. Res. 122, 742–751 (2018).
21. Subbotina, E. et al. Musclin is an activity-stimulated myokine that enhances physical endurance. Proc. Natl. Acad. Sci. U.S.A. 112, 16042–16047 (2015).
22. Liu, Y. et al. Musclin inhibits insulin activation of Akt/protein kinase B in rat skeletal muscle. J. Int. Med. Res. 36, 496–504 (2008).
23. Hu, C. et al. Osteocrin attenuates infammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity. Clin. Transl. Med. 10, e124 (2020).
24. Kanai, Y. et al. Circulating osteocrin stimulates bone growth by limiting C-type natriuretic peptide clearance. J. Clin. Investig. 127, 4136–4147 (2017).
25. Watanabe-Takano, H. et al. Mechanical load regulates bone growth via periosteal osteocrin. Cell Rep. 36, 109380 (2021).
26. Suganami, T. et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J. Am. Soc. Nephrol. 12, 2652–2663 (2001).
27. Kasahara, M. et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J. Am. Soc. Nephrol. 11, 1691–1701 (2000).
28. Makino, H. et al. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia 49, 2514–2524 (2006).
29. Koshikawa, M. et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J. Am. Soc. Nephrol. 16, 2690–2701 (2005).
30. Sanchez-Niño, M. D. et al. Te MIF receptor CD74 in diabetic podocyte injury. J. Am. Soc. Nephrol. 20, 353–362 (2009).
31. Muller, R. et al. Te mitogen-activated protein kinase p38alpha regulates tubular damage in murine anti-glomerular basement membrane nephritis. PLoS One 8, e56316 (2013).
32. Lim, A. K. et al. Role of MKK3-p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db mice. Diabetologia 52, 347–358 (2009).
33. Ortiz, A. et al. Mitogen-activated protein kinase 14 promotes AKI. J. Am. Soc. Nephrol. 28, 823–836 (2017).
34. Wilkening, A. et al. C–C chemokine receptor type 2 mediates glomerular injury and interstitial fbrosis in focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 35, 227–239 (2020).
35. Li, X. Y. et al. Prevention and possible mechanism of a purifed Laminaria japonica polysaccharide on adriamycin-induced acute kidney injury in mice. Int. J. Biol. Macromol. 148, 591–600 (2020).
36. Tacar, O., Sriamornsak, P. & Dass, C. R. Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 65, 157–170 (2013).
37. Ye, M. et al. Prednisone inhibits the focal adhesion kinase/receptor activator of NF-kappaB ligand/mitogen-activated protein kinase signaling pathway in rats with adriamycin-induced nephropathy. Mol. Med. Rep. 12, 7471–7478 (2015).
38. Bordicchia, M. et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J. Clin. Investig. 122, 1022–1036 (2012).
39. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: Te ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412 (2010).
40. Yokoi, H. et al. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int. 73, 446–455 (2008).
41. Mundel, P. et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during diferentiation of conditionally immortalized mouse podocyte cell lines. Exp. Cell Res. 236, 248–258 (1997).
42. Sawai, K. et al. Angiogenic protein Cyr61 is expressed by podocytes in anti-Ty-1 glomerulonephritis. J. Am. Soc. Nephrol. 14, 1154–1163 (2003).
43. Koga, K. et al. MicroRNA-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy. Diabetologia 58, 2169–2180 (2015).